Off-Patent Industry Criticizes CMS’ Negotiated Price Drug List

The Biosimilars Forum And AAM Have Given Their Thoughts On The Negotiations

 
• By Urtė Fultinavičiūtė
  
hands holding question marks
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Policy & Regulation

More from Generics Bulletin